中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (20): 3611-3615.doi: 10.3969/j.issn.1673-8225.2012.20.001

• 骨组织构建 bone tissue construction •    下一篇

重组人血管内皮生长因子165/重组人骨形态发生蛋白2/脱蛋白骨与深低温冷冻骨成骨能力的比较★

何盛江1，郑  华1，倪卫东2   

  1. 1重庆医科大学附属永川医院骨科，重庆市  402160；2重庆医科大学附属第一医院骨科，重庆市  400016
  • 收稿日期:2011-10-02 修回日期:2011-11-14 出版日期:2012-05-13 发布日期:2012-05-13
  • 通讯作者: 倪卫东，主任医师，重庆医科大学附属第一医院骨科，重庆市 400016 niweidong18@163.com
  • 作者简介:何盛江★，男，1968年生，重庆市人，汉族，1992年四川大学医学院毕业，硕士，主治医师，主要从事创伤骨科研究。

Comparison of osteogenesis between the recombinant human vascular endothelial growth factor 165/recombinant human bone morphogenetic protein 2/deproteinized bone and deep frozen bone 

He Sheng-jiang1, Zheng Hua1, Ni Wei-dong2   

  1. 1Department of Orthopedics, Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing  402160, China; 2Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Chongqing  400016, China
  • Received:2011-10-02 Revised:2011-11-14 Online:2012-05-13 Published:2012-05-13
  • Contact: Ni Wei-dong, Chief physician, Department of Orthopedics, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China niweidong18@163.com
  • About author:He Sheng-jiang★, Master, Attending physician, Department of Orthopedics, Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China

PDF

406

摘要：

背景：载体+骨诱导因子+生长因子模式人工骨已被证实是理想的人工骨材料。
目的：验证血管内皮生长因子+骨形态发生蛋白与脱蛋白骨复合成重组合人工骨的再血管化及成骨作用，并与深低温冷冻骨比较。
方法：新西兰大白兔左前臂制成桡骨15 mm骨缺损模型，随机分成2组，实验组植入重组血管内皮生长因子165/重组骨形态发生蛋白2/脱蛋白骨；对照组植入深低温冷冻骨。
结果与结论：16周，实验组骨缺损区骨性愈合，移植物密度接近周围正常骨组织；对照组：断端间可见较多骨痂生成，移植物密度稍高于周围正常骨组织。实验组移植物-受体介面无明显分界，达到骨愈合；对照组移植物-受体分界线模糊，部分骨愈合。第3天及第1，2，4，8周，墨汁灌注微血管分析结果显示，实验组血管生成明显多于对照组(P < 0.01)；生物力学测试结果显示，实验组三点抗弯曲应力负荷明显强于对照组(P < 0.01)。结果表明，重组血管内皮生长因子165/重组骨形态发生蛋白2/脱蛋白骨重组合人工骨能诱导断端间骨痂形成，加快移植物的血管化速度，且具有良好的生物学功能及生物力学功能。
 

关键词: 骨形态发生蛋白, 脱蛋白骨, 血管内皮生长因子, 兔, 桡骨, 移植

Abstract:

BACKGROUND: Artificial bone made by vector, osteoinductive factor and growth factor has been proved as an ideal biomaterial．
OBJECTIVE: To compare the revascularization and osteogenesis ability of the composite of recombinant human vascular endothelial growth factor 165/recombinant human bone morphogenetic protein 2/deproteinized bone (rhVEGF-165/rhBMP-2/DPB) with deep frozen bones. 
METHODS: All of the left forearm radial bones were manufactured into the models of bone defect about 15 mm. The models were randomly divided into two groups. The rhVEGF-165/rhBMP-2/DPB composite was implanted in the experimental group and the deep frozen bones were implanted in the control group.
RESULTS AND CONCLUSION: At 16 weeks, the bone in the defect area healed and the density of the grafts was close to the surrounding normal bone tissue in the experimental group; In the control group, more callus formation could be seen between the ends of the defects, and the density of the grafts was higher than that of the surrounding normal bone tissue. In the experimental group, there were no boundaries on the interface of graft-receptor, and the bone healed. In the control group, the boundaries were vague, and part of the bone healed. At 3 days and 1, 2, 4 and 8 weeks, ink perfusion microvascular analysis showed that the vascular formation in the experimental group was more than that in the control group (P < 0.01); Biomechanical testing showed that the three-point bending stress load of the experimental group was significantly stronger than of the control group    (P < 0.01). The composite of rhVEGF-165/rhBMP-2/DPB can induce callus formation, accelerate the vascularization of the graft, and have fair biological and biomechanical function.

中图分类号: